CLIK
You are here
Injection with thorotrast
Malignant neoplasm of the renal pelvis and ureter - Injection with thorotrast Factor
Last reviewed for CCPS 30 June 1999.
Preliminary questions [23675]
23676 there is some evidence that an intravascular or intracavital injection of thorotrast may be a factor in the development of the condition under consideration.
20665 the veteran has had an intravascular or intracavital injection of thorotrast at some time.
23677 the veteran has had an intravascular or intracavital injection of thorotrast to the abdominal or pelvic organs at some time. the veteran has had an intravascular injection of thorotrast or an intracavital injection of thorotrast to the abdominal or pelvic organs before the clinical onset of malignant neoplasm of the renal pelvis and ureter. 23679 — the veteran has established the causal connection between the injection with thorotrast and VEA service for the clinical onset of malignant neoplasm of the renal pelvis and ureter. 23680 — the veteran has established the causal connection between the injection with thorotrast and operational service for the clinical onset of malignant neoplasm of the renal pelvis and ureter. or 23681 — the veteran has established the causal connection between the injection with thorotrast and eligible service for the clinical onset of malignant neoplasm of the renal pelvis and ureter. Clinical onset and operational service [23680] or 20676 — the identified illness or injury for which the intravascular or intracavital injection of thorotrast to the abdominal or pelvic organs was given is causally related to operational service. Clinical onset and eligible service [23681]
20677 — the identified illness or injury for which the intravascular or intracavital injection of thorotrast to the abdominal or pelvic organs was given is causally related to eligible service.